Fiduciary Trust Co Sells 1,062 Shares of Moderna, Inc. (NASDAQ:MRNA)

Fiduciary Trust Co cut its position in Moderna, Inc. (NASDAQ:MRNA) by 0.7% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 161,983 shares of the company’s stock after selling 1,062 shares during the quarter. Fiduciary Trust Co’s holdings in Moderna were worth $10,825,000 as of its most recent SEC filing.

Other hedge funds have also recently made changes to their positions in the company. Intrinsic Value Partners LLC grew its stake in shares of Moderna by 91.1% in the third quarter. Intrinsic Value Partners LLC now owns 51,392 shares of the company’s stock worth $3,435,000 after purchasing an additional 24,505 shares during the last quarter. Banco Santander S.A. acquired a new position in Moderna during the 3rd quarter worth about $3,550,000. John G Ullman & Associates Inc. grew its position in shares of Moderna by 341.3% in the 3rd quarter. John G Ullman & Associates Inc. now owns 49,650 shares of the company’s stock valued at $3,318,000 after buying an additional 38,400 shares during the last quarter. Sumitomo Mitsui Trust Group Inc. increased its stake in shares of Moderna by 11.6% in the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,614,313 shares of the company’s stock valued at $107,885,000 after buying an additional 167,596 shares during the period. Finally, Vontobel Holding Ltd. raised its position in shares of Moderna by 148.2% during the third quarter. Vontobel Holding Ltd. now owns 116,088 shares of the company’s stock worth $7,758,000 after acquiring an additional 69,313 shares during the last quarter. 75.33% of the stock is owned by institutional investors and hedge funds.

Moderna Stock Performance

Shares of MRNA stock opened at $43.39 on Thursday. The company has a current ratio of 4.39, a quick ratio of 4.20 and a debt-to-equity ratio of 0.05. The firm has a fifty day simple moving average of $53.32 and a two-hundred day simple moving average of $92.28. Moderna, Inc. has a 12 month low of $35.80 and a 12 month high of $170.47. The firm has a market capitalization of $16.70 billion, a PE ratio of -7.46 and a beta of 1.69.

Moderna (NASDAQ:MRNA) last issued its quarterly earnings data on Thursday, November 7th. The company reported $0.03 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.89) by $1.92. Moderna had a negative net margin of 43.77% and a negative return on equity of 17.68%. The firm had revenue of $1.90 billion during the quarter, compared to analysts’ expectations of $1.25 billion. During the same period last year, the company earned ($1.39) earnings per share. The business’s revenue was up 3.8% on a year-over-year basis. Analysts forecast that Moderna, Inc. will post -9.44 EPS for the current fiscal year.

Insider Buying and Selling at Moderna

In other news, CFO James M. Mock sold 715 shares of the firm’s stock in a transaction that occurred on Monday, October 7th. The stock was sold at an average price of $60.12, for a total value of $42,985.80. Following the transaction, the chief financial officer now owns 9,505 shares in the company, valued at $571,440.60. This trade represents a 7.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In the last quarter, insiders sold 1,147 shares of company stock worth $76,245. Insiders own 15.70% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts recently commented on the company. UBS Group reduced their target price on Moderna from $140.00 to $108.00 and set a “buy” rating on the stock in a report on Thursday, October 24th. TD Cowen reduced their price objective on shares of Moderna from $70.00 to $60.00 and set a “hold” rating on the stock in a research note on Friday, September 13th. Barclays lowered their target price on shares of Moderna from $125.00 to $111.00 and set an “overweight” rating for the company in a research note on Friday, November 8th. Deutsche Bank Aktiengesellschaft raised shares of Moderna from a “sell” rating to a “hold” rating and cut their price target for the company from $85.00 to $80.00 in a research report on Wednesday, August 7th. Finally, Sanford C. Bernstein initiated coverage on Moderna in a research report on Thursday, October 17th. They issued a “market perform” rating and a $55.00 price objective for the company. Three research analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, five have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, Moderna currently has a consensus rating of “Hold” and an average price target of $83.26.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.